Logo

Jerini s Peptide IP to Help Alcon Develop Drugs for Opthamology

Jan 21, 2005

NEW YORK, Jan. 21 (GenomeWeb News) - Jerini has entered into a strategic discovery and development collaboration with Alcon Research to generate new drugs for opthamology.

 

The companies will employ Jerini's Peptides-to-Drugs discovery platform, including SPOT, pepSPOT, and pepMED, along with other technologies to generate peptidomemetic and small molecule drug candidates and validate their utility for the treatment of eye diseases.

 

Jerini will receive up-front and license fees, as well as personnel funding, milestone payments, and worldwide royalties on commercial sales of products resulting from the collaboration.

 

Financial terms of the agreement were not disclosed.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.